Cytokinetics (NASDAQ:CYTK) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Cytokinetics (NASDAQ:CYTK) had its price target increased by equities researchers at Citizens Jmp from $88.00 to $96.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s price objective points to a potential upside of 53.28% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Truist Financial raised their price objective on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd. Barclays started coverage on shares of Cytokinetics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 target price on the stock. B. Riley Financial boosted their price target on shares of Cytokinetics from $90.00 to $108.00 and gave the company a “buy” rating in a research report on Wednesday, January 21st. JPMorgan Chase & Co. upped their price objective on shares of Cytokinetics from $70.00 to $74.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Finally, Needham & Company LLC lifted their target price on Cytokinetics from $72.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Seventeen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and a consensus target price of $88.83.

Cytokinetics Price Performance

Cytokinetics stock opened at $62.63 on Wednesday. The stock has a market cap of $7.66 billion, a PE ratio of -9.59 and a beta of 0.54. The stock’s fifty day moving average is $64.21 and its two-hundred day moving average is $58.38. Cytokinetics has a 1-year low of $29.31 and a 1-year high of $70.98.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the prior year, the company posted ($1.26) earnings per share. The business’s quarterly revenue was up 4.9% on a year-over-year basis. On average, research analysts expect that Cytokinetics will post -5.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,200 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the completion of the sale, the executive vice president directly owned 138,552 shares of the company’s stock, valued at approximately $8,484,924.48. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Wendell Wierenga sold 20,000 shares of Cytokinetics stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the transaction, the director owned 32,444 shares in the company, valued at $2,145,846.16. This trade represents a 38.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 151,385 shares of company stock valued at $9,817,158 in the last ninety days. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

Several institutional investors have recently bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new stake in shares of Cytokinetics in the 4th quarter worth $27,000. Kestra Advisory Services LLC purchased a new position in Cytokinetics during the fourth quarter worth about $29,000. TD Waterhouse Canada Inc. purchased a new stake in Cytokinetics in the 4th quarter valued at approximately $32,000. Northwestern Mutual Wealth Management Co. increased its position in Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 171 shares during the period. Finally, Quarry LP acquired a new position in Cytokinetics during the 3rd quarter worth approximately $30,000.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reiterates a “Buy” and models near‑term quarterly EPS (Q1: -$1.57, Q2: -$1.61, Q4: -$1.89) while assigning a $136 price target — a substantial upside that supports longer‑term investor interest. HC Wainwright estimates
• Positive Sentiment: Analysts have been raising price targets: Citizens JMP to $96 (market outperform), Leerink Partners to $84 (outperform), and Needham to $85 (buy) — these upgrades add upward pressure on sentiment. Benzinga price target coverage
• Positive Sentiment: Zacks notes Cytokinetics is advancing Myqorzo launch plans after FDA activity and highlights a ~$1.22B cash position, which supports funding for commercialization and 2026 catalysts. Myqorzo launch & cash runway
• Positive Sentiment: Retail/permissioned coverage and bullish opinion pieces (e.g., Villanovan profile) are promoting a buy case based on pipeline and commercialization upside. Why Cytokinetics Is a Buy
• Neutral Sentiment: Q4 earnings call and transcript coverage are available for deeper read‑throughs of management commentary on margins, SG&A, and launch timing (useful for assessing execution risk). Earnings call transcript (InsiderMonkey) Earnings transcript (Seeking Alpha) Earnings transcript (Yahoo)
• Neutral Sentiment: Reported short‑interest data appears anomalous/zero in the latest release, so there’s no clear short‑squeeze signal from those figures. (No actionable short‑pressure evidence.)
• Negative Sentiment: Q4 results showed a slightly wider-than-expected loss (EPS -$1.50 vs. estimate -$1.48) and higher expenses year‑over‑year — a near‑term negative that likely pressured the stock despite revenue outperformance. Q4 results coverage

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.